Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection

J Infect Dis. 2011 Nov;204 Suppl 3(Suppl 3):S1090-7. doi: 10.1093/infdis/jir379.


Background: Outbreaks of filoviral hemorrhagic fever occur sporadically and unpredictably across wide regions in central Africa and overlap with the occurrence of other infectious diseases of public health importance.

Methods: As a proof of concept we developed a bivalent recombinant vaccine based on vesicular stomatitis virus (VSV) expressing the Zaire ebolavirus (ZEBOV) and Andes virus (ANDV) glycoproteins (VSVΔG/Dual) and evaluated its protective efficacy in the common lethal Syrian hamster model. Hamsters were vaccinated with VSVΔG/Dual and were lethally challenged with ZEBOV or ANDV. Time to immunity and postexposure treatment were evaluated by immunizing hamsters at different times prior to and post ZEBOV challenge.

Results: A single immunization with VSVΔG/Dual conferred complete and sterile protection against lethal ZEBOV and ANDV challenge. Complete protection was achieved with an immunization as close as 3 days prior to ZEBOV challenge, and 40% of the animals were even protected when treated with VSVΔG/Dual one day postchallenge. In comparison to the monovalent VSV vaccine, the bivalent vaccine has slightly reduced postexposure efficacy most likely due to its restricted lymphoid organ replication.

Conclusions: Bivalent VSV vectors are a feasible approach to vaccination against multiple pathogens.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Animals
  • Chlorocebus aethiops
  • Cricetinae
  • Disease Models, Animal
  • Ebola Vaccines / standards*
  • HEK293 Cells
  • Hemorrhagic Fever, Ebola / prevention & control*
  • Humans
  • Mesocricetus
  • Post-Exposure Prophylaxis
  • Vaccines, Synthetic / standards
  • Vero Cells
  • Vesiculovirus / genetics*
  • Virus Replication


  • Ebola Vaccines
  • Vaccines, Synthetic